WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2023)
Top biotech stocks in 2023 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Country
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
ARCT
ARCTURUS THERAPEUTICS HOLDINGS INC
United States
$681.98M26,723,33286.90%13.10%Net SellingNet Selling
GMAB
GENMAB A
Denmark
$20.07B66,067,48171.65%0.00%
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
United States
$1.70B58,571,94461.68%38.32%Net Selling
ZYME
ZYMEWORKS INC
Canada
$611.12M70,001,98760.37%39.63%Net Buying
VYGR
VOYAGER THERAPEUTICS INC
United States
$303.57M43,995,36347.73%52.27%Net BuyingNet Selling
INCY
INCYTE CORP
United States
$11.81B224,109,23878.84%21.16%Net SellingNet Selling
CPRX
CATALYST PHARMACEUTICALS INC
United States
$1.51B106,611,45675.93%17.33%Net Buying
FBIO
FORTRESS BIOTECH INC
United States
$17.44M8,942,75155.71%44.29%Net BuyingNet Buying
UTHR
UNITED THERAPEUTICS CORP
United States
$10.83B46,993,60187.40%12.60%Net SellingNet Selling
MEIP
MEI PHARMA INC
United States
$40.91M6,662,85714.83%85.17%Net BuyingNet Buying
AMLX
AMYLYX PHARMACEUTICALS INC
United States
$871.65M67,517,75352.27%47.73%Net SellingNet Buying
HALO
HALOZYME THERAPEUTICS INC
United States
$5.24B132,098,11077.88%22.12%Net SellingNet Buying
BMRN
BIOMARIN PHARMACEUTICAL INC
United States
$16.53B188,368,17194.07%1.48%Net Selling
LGND
LIGAND PHARMACEUTICALS INC
United States
$1.01B17,435,95814.59%85.41%Net SellingNet Buying
EXEL
EXELIXIS INC
United States
$6.55B310,974,11383.99%3.62%Net SellingNet Selling
OCUP
OCUPHIRE PHARMA INC
United States
$61.12M22,637,6001.25%98.75%
PLX
PROTALIX BIOTHERAPEUTICS INC
Israel
$99.21M72,952,1246.32%93.68%Net BuyingNet Buying
OBIO
ORCHESTRA BIOMED HOLDINGS INC
United States
$232.69M35,743,97236.63%49.04%Net Buying
CRSP
CRISPR THERAPEUTICS AG
Switzerland
$5.61B79,432,44662.71%37.29%Net Buying
MRVI
MARAVAI LIFESCIENCES HOLDINGS INC
United States
$1.29B251,282,65835.23%64.77%Net SellingNet Selling
AGIO
AGIOS PHARMACEUTICALS INC
United States
$1.24B55,891,28474.98%25.02%Net SellingNet Selling
TECH
BIO-TECHNE CORP
United States
$9.75B158,150,37994.93%2.36%Net BuyingNet Buying
CRNX
CRINETICS PHARMACEUTICALS INC
United States
$2.09B66,799,25784.76%15.24%Net SellingNet Buying
CORT
CORCEPT THERAPEUTICS INC
United States
$2.62B103,081,35729.98%70.02%Net BuyingNet Buying
ALLO
ALLOGENE THERAPEUTICS INC
United States
$434.15M168,276,66262.00%38.00%Net Selling
VNDA
VANDA PHARMACEUTICALS INC
United States
$204.24M57,531,99957.42%42.58%Net Selling
MRKR
MARKER THERAPEUTICS INC
United States
$25.07M8,889,0201.28%98.72%
AXSM
AXSOME THERAPEUTICS INC
United States
$3.11B47,319,54770.49%29.51%Net SellingNet Selling
LIFE
ATYR PHARMA INC
United States
$73.20M58,560,06163.41%26.02%Net BuyingNet Buying
CLGN
COLLPLANT BIOTECHNOLOGIES LTD
Israel
$65.35M11,405,39413.40%0.00%
SPRO
SPERO THERAPEUTICS INC
United States
$61.48M52,999,31726.76%62.75%Net SellingNet Selling
MGNX
MACROGENICS INC
United States
$464.60M62,029,44771.25%28.75%Net BuyingNet Buying
CRMD
CORMEDIX INC
United States
$184.17M54,812,04232.61%10.43%Net BuyingNet Buying
REGN
REGENERON PHARMACEUTICALS INC
United States
$87.28B108,946,98469.06%30.94%Net SellingNet Selling
ENTX
ENTERA BIO LTD
Israel
$20.23M28,813,9528.95%4.08%Net Buying
SPRY
ARS PHARMACEUTICALS INC
United States
$462.23M95,997,25245.22%54.78%Net BuyingNet Buying
LUMO
LUMOS PHARMA INC
United States
$23.82M7,914,58218.18%81.82%Net Selling
DNLI
DENALI THERAPEUTICS INC
United States
$2.53B138,196,84855.82%44.18%Net SellingNet Selling
KNSA
KINIKSA PHARMACEUTICALS LTD
Bermuda
$1.10B70,338,35449.57%10.00%Net SellingNet Selling
VRTX
VERTEX PHARMACEUTICALS INC
United States
$89.43B257,683,18489.97%1.48%Net SellingNet Selling
ADMA
ADMA BIOLOGICS INC
United States
$840.60M225,967,66875.02%24.98%Net SellingNet Buying
ARDX
ARDELYX INC
United States
$949.44M232,137,70936.14%63.86%Net SellingNet Selling
APRE
APREA THERAPEUTICS INC
United States
$14.01M3,736,6731.46%98.54%Net Buying
BLUE
BLUEBIRD BIO INC
United States
$419.85M109,336,21181.79%11.59%Net SellingNet Selling
KZR
KEZAR LIFE SCIENCES INC
United States
$63.10M72,692,96376.33%21.80%Net Selling
RNA
AVIDITY BIOSCIENCES INC
United States
$524.64M74,101,25483.37%16.63%Net Buying
BGNE
BEIGENE LTD
Cayman Islands
$19.35B1,359,497,6243.47%34.77%Net SellingNet Selling
RNAC
CARTESIAN THERAPEUTICS INC
United States
$166.84M155,204,18233.13%42.09%Net SellingNet Selling
PLUR
PLURI INC
Israel
$24.47M41,480,1720.52%99.48%Net Selling
DBVT
DBV TECHNOLOGIES SA
France
$152.71M96,288,55346.10%15.38%Net Buying
FUSN
FUSION PHARMACEUTICALS INC
Canada
$343.20M72,405,84067.01%32.99%
VERV
VERVE THERAPEUTICS INC
United States
$760.57M63,752,74860.73%39.27%Net Buying
CBAY
CYMABAY THERAPEUTICS INC
United States
$2.04B113,403,35386.57%13.43%Net BuyingNet Buying
LPCN
LIPOCINE INC
United States
$13.13M5,315,8305.94%94.06%Net Buying
IMGN
IMMUNOGEN INC
United States
$4.25B266,264,27491.64%3.03%Net BuyingNet Selling
ALT
ALTIMMUNE INC
United States
$167.10M53,728,87132.55%67.45%Net Buying
IGMS
IGM BIOSCIENCES INC
United States
$338.69M58,394,05638.22%52.45%Net BuyingNet Selling
CGEN
COMPUGEN LTD
Israel
$56.91M88,233,76614.30%0.00%
XCUR
EXICURE INC
United States
$4.32M8,648,3070.95%99.05%Net Selling
FRTX
FRESH TRACKS THERAPEUTICS INC
United States
$4.71M5,973,3061.04%98.96%Net SellingNet Selling
FULC
FULCRUM THERAPEUTICS INC
United States
$281.91M61,822,55462.18%37.82%Net Buying
IMMP
IMMUTEP LTD
Australia
$220.84M1,187,306,2090.16%0.00%
IDYA
IDEAYA BIOSCIENCES INC
United States
$1.99B64,459,47288.86%11.14%Net BuyingNet Selling
DNTH
DIANTHUS THERAPEUTICS INC
United States
$171.59M14,817,76228.11%71.89%Net SellingNet Buying
ANIX
ANIXA BIOSCIENCES INC
United States
$103.77M31,070,02212.64%86.79%Net BuyingNet Buying
PGEN
PRECIGEN INC
United States
$278.79M248,919,09624.34%72.12%Net BuyingNet Buying
KRYS
KRYSTAL BIOTECH INC
United States
$2.85B28,206,33074.63%25.37%Net SellingNet Selling
CMRX
CHIMERIX INC
United States
$84.45M88,891,30045.13%31.74%Net BuyingNet Buying
BCYC
BICYCLE THERAPEUTICS PLC
United Kingdom
$588.39M42,421,54862.65%37.35%Net SellingNet Selling
ORTX
ORCHARD THERAPEUTICS PLC
United Kingdom
$369.18M227,610,4397.28%13.37%Net Buying
LSTA
LISATA THERAPEUTICS INC
United States
$20.27M8,139,4490.78%99.22%Net SellingNet Selling
PRTA
PROTHENA CORP PUBLIC LTD CO
Ireland
$1.74B53,665,34952.72%47.28%Net BuyingNet Buying
FBRX
FORTE BIOSCIENCES INC
United States
$16.82M36,335,10545.96%21.83%Net BuyingNet Selling
CRDF
CARDIFF ONCOLOGY INC
United States
$55.85M44,677,16912.21%34.53%Net BuyingNet Buying
ALDX
ALDEYRA THERAPEUTICS INC
United States
$158.82M58,822,08364.21%33.43%Net SellingNet Selling
ATOS
ATOSSA THERAPEUTICS INC
United States
$97.49M125,304,06412.90%15.20%Net BuyingNet Selling
JAZZ
JAZZ PHARMACEUTICALS PLC
Ireland
$7.21B62,956,91326.62%73.38%Net SellingNet Selling
YMAB
Y-MABS THERAPEUTICS INC
United States
$253.01M43,621,61845.12%38.03%Net BuyingNet Selling
NRBO
NEUROBO PHARMACEUTICALS INC
United States
$16.69M38,812,5181.05%67.02%
LXRX
LEXICON PHARMACEUTICALS INC
United States
$269.42M244,924,69521.06%78.94%Net BuyingNet Buying
ARVN
ARVINAS INC
United States
$1.34B55,025,50469.10%30.90%Net Selling
GTHX
G1 THERAPEUTICS INC
United States
$87.62M51,843,66921.11%46.30%Net Selling
ATXS
ASTRIA THERAPEUTICS INC
United States
$166.60M36,296,19162.52%37.48%Net BuyingNet Buying
CUE
CUE BIOPHARMA INC
United States
$103.78M45,123,28131.06%10.04%Net Buying
PRTC
PURETECH HEALTH PLC
United States
$576.63M278,566,3060.03%0.00%
AVXL
ANAVEX LIFE SCIENCES CORP
United States
$556.55M82,086,51130.50%5.04%Net Buying
LQDA
LIQUIDIA CORP
United States
$458.88M64,905,49533.30%66.70%Net SellingNet Selling
AUPH
AURINIA PHARMACEUTICALS INC
Canada
$1.25B143,608,16434.77%2.40%Net Selling
AUTL
AUTOLUS THERAPEUTICS PLC
United Kingdom
$791.41M173,936,79463.54%0.00%
DOMH
DOMINARI HOLDINGS INC
United States
$12.08M5,345,3128.37%91.63%Net BuyingNet Buying
ZLAB
ZAI LAB LTD
China
$2.77B988,387,4303.98%1.97%Net BuyingNet Buying
PBYI
PUMA BIOTECHNOLOGY INC
United States
$195.04M47,571,33254.04%44.54%Net BuyingNet Selling
GRTS
GRITSTONE BIO INC
United States
$123.94M95,342,05550.99%22.69%Net Buying
SEER
SEER INC
United States
$106.59M63,825,21356.70%43.30%Net BuyingNet Buying
PNT
POINT BIOPHARMA GLOBAL INC
United States
$1.47B106,569,23157.83%22.10%Net Buying
NVO
NOVO NORDISK A S
Denmark
$462.52B4,560,000,0006.56%0.00%
GNFT
GENFIT SA
France
$161.96M49,834,9832.32%0.00%
VTGN
VISTAGEN THERAPEUTICS INC
United States
$100.53M27,023,0389.82%90.18%Net Buying
ARQT
ARCUTIS BIOTHERAPEUTICS INC
United States
$192.54M94,382,07470.70%29.30%Net BuyingNet Buying
BRTX
BIORESTORATIVE THERAPIES INC
United States
$9.23M4,706,9170.36%99.64%Net BuyingNet Buying

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Nov 2023?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Arcturus Therapeutics Holdings (NASDAQ:ARCT)


Arcturus Therapeutics Holdings (NASDAQ:ARCT) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Arcturus Therapeutics Holdings has seen its stock return 58.61% over the past year, overperforming other biotech stocks by 86 percentage points.

Arcturus Therapeutics Holdings has an average 1 year price target of $58.67, an upside of 129.89% from Arcturus Therapeutics Holdings's current stock price of $25.52.

Arcturus Therapeutics Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Arcturus Therapeutics Holdings, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Genmab A (NASDAQ:GMAB)


Genmab A (NASDAQ:GMAB) is the second best biotech stock with a Zen Score of 65, which is 42 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Genmab A has seen its stock lose -32.23% over the past year, underperforming other biotech stocks by -4 percentage points.

Genmab A has an average 1 year price target of $45.25, an upside of 48.95% from Genmab A's current stock price of $30.38.

Genmab A stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Genmab A, 50% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 25% have issued a Strong Sell.

3. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the third best biotech stock with a Zen Score of 64, which is 41 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -49.75% over the past year, underperforming other biotech stocks by -22 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $48.71, an upside of 67.46% from Harmony Biosciences Holdings's current stock price of $29.09.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Harmony Biosciences Holdings, 57.14% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 14.29% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 7 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Kineta (NASDAQ:KA)


Kineta (NASDAQ:KA) has an annual dividend yield of 305.18%, which is 253 percentage points higher than the biotech industry average of 52.16%.

Kineta's dividend payout ratio of -16,683.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 28.5%, which is -24 percentage points lower than the biotech industry average of 52.16%.

Mei Pharma's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

3. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of 15.28%, which is -37 percentage points lower than the biotech industry average of 52.16%.

Carisma Therapeutics's dividend payout ratio of -9.6% indicates that its high dividend yield might not be sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -0.9% in the last day, and up 0.5% over the last week. Tharimmune was the among the top losers in the biotechnology industry, dropping -72.36% yesterday.

Tharimmune shares are trading lower after the company announced pricing of a $10 million public offering.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Fortress Biotech (NASDAQ:FBIO)


Fortress Biotech (NASDAQ:FBIO) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Fortress Biotech has a valuation score of 100, which is 81 points higher than the biotech industry average of 19. It passed 7 out of 7 valuation due diligence checks.

Fortress Biotech's stock has dropped -81.34% in the past year. It has underperformed other stocks in the biotech industry by -54 percentage points.

2. Arcturus Therapeutics Holdings (NASDAQ:ARCT)


Arcturus Therapeutics Holdings (NASDAQ:ARCT) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Arcturus Therapeutics Holdings has a valuation score of 100, which is 81 points higher than the biotech industry average of 19. It passed 7 out of 7 valuation due diligence checks.

Arcturus Therapeutics Holdings's stock has gained 58.61% in the past year. It has overperformed other stocks in the biotech industry by 86 percentage points.

3. Aprea Therapeutics (NASDAQ:APRE)


Aprea Therapeutics (NASDAQ:APRE) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Aprea Therapeutics has a valuation score of 71, which is 52 points higher than the biotech industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Aprea Therapeutics's stock has dropped -49.38% in the past year. It has underperformed other stocks in the biotech industry by -22 percentage points.

Are biotech stocks a good buy now?

52.82% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 103.72% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 12.55x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.